$140.2 M

BLPH Mkt cap, 14-Jun-2018
Bellerophon Therapeutics Net income (Q1, 2018)4.1 M
Bellerophon Therapeutics EBIT (Q1, 2018)-8.5 M
Bellerophon Therapeutics Cash, 31-Mar-201828.4 M

Bellerophon Therapeutics Financials

Bellerophon Therapeutics Income Statement

Annual

USDFY, 2016

R&D expense

5.1 m

General and administrative expense

2.2 m

Operating expense total

7.3 m

EBIT

(7.3 m)

Income tax expense

(438 k)

Net Income

(7.4 m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

R&D expense

9.5 m8.4 m7.1 m5.1 m4 m2.5 m3.3 m6.4 m

General and administrative expense

4.6 m3.4 m4.3 m2 m1.2 m1.7 m1.4 m2.1 m

Operating expense total

14.1 m11.9 m11.4 m7.1 m5.2 m4.2 m4.8 m8.5 m

EBIT

(12.9 m)(11.6 m)(11.2 m)(7.1 m)(5.2 m)(4.2 m)(4.8 m)(8.5 m)

Interest income

19 k27 k27 k30 k22 k22 k27 k99 k

Income tax expense

5.4 m

Net Income

(12.9 m)(11.6 m)(11.1 m)(7.1 m)(5.1 m)(4.2 m)(19.1 m)4.1 m

Bellerophon Therapeutics Balance Sheet

Annual

USDFY, 2016

Cash

14.5 m

Current Assets

26.5 m

PP&E

1.4 m

Total Assets

29.7 m

Accounts Payable

2.8 m

Current Liabilities

6.5 m

Total Liabilities

11.7 m

Additional Paid-in Capital

142.2 m

Retained Earnings

(124.5 m)

Total Equity

18 m

Financial Leverage

1.7 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

62.9 m48.5 m23.9 m1.3 m1.3 m3.9 m13.5 m28.4 m

Current Assets

73.6 m60.9 m46.9 m23.1 m18.6 m17.5 m23.2 m34.8 m

PP&E

1.6 m1.5 m1.8 m1.7 m1.6 m1.5 m1.3 m935 k

Total Assets

75.2 m62.4 m49.2 m31.2 m26.3 m22.8 m25.8 m35.9 m

Accounts Payable

659 k966 k934 k641 k2 m2.2 m3.9 m4.6 m

Current Liabilities

12.8 m11.2 m8.6 m7.3 m6.2 m4.8 m6.1 m8.4 m

Total Liabilities

33.7 m

Additional Paid-in Capital

131.5 m132.8 m134.9 m144.1 m176.9 m

Retained Earnings

(67.1 m)(78.7 m)(89.9 m)(107.7 m)(112.9 m)(117.1 m)(143.6 m)(175.2 m)

Total Equity

23.9 m20.1 m18 m800 k2.2 m

Financial Leverage

1.3 x1.3 x1.3 x32.2 x16.2 x

Bellerophon Therapeutics Cash Flow

Annual

USDFY, 2016

Net Income

(23.8 m)

Depreciation and Amortization

(400 k)

Cash From Operating Activities

(17.2 m)

Cash From Investing Activities

12.2 m

Cash From Financing Activities

13.2 m

Free Cash Flow

(17.2 m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(12.9 m)(11.6 m)(11.1 m)(7.1 m)(5.1 m)(4.2 m)(19.1 m)4.1 m

Depreciation and Amortization

91 k

Accounts Payable

659 k966 k934 k641 k2 m2.2 m3.9 m

Cash From Operating Activities

(444 k)

Cash From Financing Activities

(28 k)

Bellerophon Therapeutics Ratios

USDY, 2018

Financial Leverage

16.2 x
Report incorrect company information